The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial.
Miguel Martin
Consultant or Advisory Role - Amgen; Genomic Health; Roche
Ana Lluch
No relevant relationships to disclose
Amparo Ruiz
No relevant relationships to disclose
Manuel Ruiz Borrego
No relevant relationships to disclose
Agust Barnadas
No relevant relationships to disclose
Sonia Gonzalez
No relevant relationships to disclose
Lourdes Calvo
No relevant relationships to disclose
Mireia Margeli Vila
No relevant relationships to disclose
Antonio Anton
No relevant relationships to disclose
Alvaro Rodriguez-Lescure
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Honoraria - Bristol-Myers Squibb
Miguel Angel SeguĂ­-Palmer
No relevant relationships to disclose
Montserrat Munoz-Mateu
No relevant relationships to disclose
Joan Dorca Ribugent
No relevant relationships to disclose
Jose Manuel Lopez-Vega
No relevant relationships to disclose
Cesar Mendiola Fernandez
No relevant relationships to disclose
Raquel Andres
No relevant relationships to disclose
Arrate Plazaola
No relevant relationships to disclose
Cesar Rodriguez
No relevant relationships to disclose
Maria Isabel Casas
No relevant relationships to disclose
Eva Maria Carrasco
No relevant relationships to disclose